Beacon Therapeutics may have found a guiding light in a disease area where other companies have stumbled with its laruparetigene zovaparvovec (laru-zova), a gene therapy that proved early improvements ...
Genetic diseases are a compelling target for viral gene therapy, but the results can be spotty at best. There's good news, though. On Wednesday, researchers presented evidence from a breakthrough gene ...
A Johnson & Johnson gene therapy in development for an inherited vision-loss disorder has failed a Phase 3 study, the latest clinical research setback for a rare eye disease that so far has no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results